Official Publication of the Society for Laboratory Automation and Screening
This message contains images. If you don't see images, click here to view.
Advertise in this news brief.


Text version   RSS   Subscribe   Unsubscribe   Archive   Media Kit September 27, 2017    SLAS2018    Moving? New job? Let SLAS know.      








Heart-on-a-Chip: An Investigation of the Influence of Static and Perfusion Conditions on Cardiac (H9C2) Cell Proliferation, Morphology and Alignment
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A new report in the October 2017 issue of SLAS Technology shows how microsystems can be used to understand processes in heart tissue in detail and to test newly developed compounds applied in the treatment of cardiac diseases. Authors from Warsaw University of Technology (Poland) and École Polytechnique Fédérale de Lausanne (Switzerland) report their results support their hypothesis that external stimulation (continuous medium flow) enhances both the growth and parallel orientation of cardiac (H9C2) cells; and that the use of verapamil, L-type calcium channel blocker, inhibits H9C2 cell proliferation in cultures performed under perfusion conditions.

Full access is available to nonmembers for a limited time. Full access always is available to subscribing SLAS Premier members and all Premier Plus members. Listen to the SLAS Technology podcast with Dr. Elzbieta Jastrzebska.


Abstracts Due Oct. 14 for SLAS Discovery Special Issue on High-Throughput Flow Cytometry in Drug Discovery
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
SLAS Discovery Guest Editors Mei Ding of AstraZeneca and Bruce S. Edwards of the University of New Mexico invite special issue manuscript proposals (abstracts) on high-throughput flow cytometry (HTFC) applications for drug discovery or target discovery; HTFC for antibody generation screening, biomarker discovery, biochemical applications; HTFC using multiplexing approaches; HTFC as an alternative for other assay platforms; insights and opinions on HTFC assay design and development; novel assays using HTFC; reagent developments for HTFC applications; developments in HTFC instruments and automation; and advances in HTFC data analysis software.

Invited authors will be notified by Oct. 10, and final manuscripts are due Feb. 1, 2018.

NEW at SLAS2018: SLAS Ignite Academic Theater
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
SLAS is proud to have served as a venue for collaboration since the Society's founding, bringing together a diverse community of engineers, researchers, scientists, business leaders and pioneering academic experts to advance scientific research using the latest technologies and insights provided by fellow members of the SLAS community.

The Society is adding one more way for academic researchers and industry scientists to connect and collaborate — SLAS Ignite Academic Theater presentations. This new program enables academic research institutions to showcase their capabilities and latest research to industry professionals responsible for partnerships and contract relations.

The inaugural class of SLAS Ignite Academic Theater presenters will be selected by a review committee from abstracts submitted by Oct. 16. SLAS2018 Academic Theater presentations should be no longer than 10 minutes, and time will be added for Q&A.


Promoted by Surmodics

SLAS Author Workshops at ELRIG, Oct. 3-4
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
Even the most groundbreaking scientific breakthroughs need to be well written to be published. The SLAS Author Workshops at ELRIG Drug Discovery 2017 will show researchers how writing a scientific paper begins before experiments are even finished. When results start telling a story, preparation of a working outline helps focus continued experiments. As researchers build out from an outline, keeping the central message in focus, ensuring the key takeaway points are clear and looking for a logical progression in the data eases the transition from an outline to a narrative that successfully illustrates originality of the research; highlights novel insights and conclusions; demonstrates how the work extends what is already known, how it’s different from work cited in the paper and how it’s different from work NOT cited in the paper.

Join SLAS Discovery Editorial Board member and guest editor Rob Howes, Ph.D. (AstraZeneca) at ELRIG in Liverpool, UK. Learn more about the SLAS journals (SLAS Discovery and SLAS Technology).

From the SLAS President: Making a Case for Attending SLAS2018
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
"Like any proposed investment, your request to attend SLAS2018 should include thoughtful and meaningful rationale that illustrates how your participation will help advance your scientific objectives and your lab's priorities," says SLAS President Scott Atkin.

He offers a few examples based on feedback from previous attendees of the SLAS International Conference and Exhibition, such as: What current issues have you been struggling with? Do any of the SLAS2018 presentations address these issues? Do any of the exhibitors offer potential solutions? Read more in the SLAS Electronic Laboratory Neighborhood e-zine.

Automate your nucleic acid analysis

Take your automated nucleic acid QC to the next level with Advanced Analytical Technologies, Inc. and Tecan Group Ltd. The Fragment Analyzer INFINITY Automated CE System seamlessly integrates with the robotic arm of the Freedom EVO line of automation solutions from Tecan, providing you with reproducible and reliable QC analysis.


Streamlined Process Opens Drug Development to a New Class of Steroids    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers at Dartmouth College have developed a technique to produce synthetic steroids that could pave the way for a cascade of new drug discoveries. The process, published in the journal Nature Chemistry, facilitates access to rare, mirror-image isomers of naturally occurring steroid structures. The technique significantly reduces the expense and time needed to develop therapeutics from a pharmaceutically privileged yet underexplored collection of molecules. More

Metallopeptide Catalyst Eases Synthesis of Antibody-Drug Conjugates
Chemical & Engineering News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Antibody-drug conjugates are promising next-generation cancer therapies that can target and selectively kill malignant cells while sparing healthy ones. These conjugates — in which a drug is bound to an antibody through a small chemical linker — harness the antibody's ability to recognize markers specific to cancer cells and bring the potent drugs to their intended site of action. More


Locking Down the Big Bang of Immune Cells
Lab Manager    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Intricate human physiological features such as the immune system require exquisite formation and timing to develop properly. Genetic elements must be activated at just the right moment, across vast distances of genomic space. "Promoter" areas, locations where genes begin to be expressed, must be paired precisely with "enhancer" clusters, where cells mature to a targeted function. More

Proton-Based Structural Analysis of a Heptahelical Transmembrane Protein in Lipid Bilayers
Journal of the American Chemical Society    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The structures and properties of membrane proteins in lipid bilayers are expected to closely resemble those in native cell-membrane environments, although they have been difficult to elucidate. By performing solid-state NMR measurements at very fast (100 kHz) magic-angle spinning rates and at high (23.5 T) magnetic field, severe sensitivity and resolution challenges are overcome, enabling the atomic-level characterization of membrane proteins in lipid environments. More

Sponsored Content

Poliovirus Therapy Induces Immune Responses Against Cancer
Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells to evade the immune system. Describing this process in a paper in the journal Science Translational Medicine, Duke Cancer Institute researchers provide the first published insight into the workings of a therapy that has shown promise in early clinical trials. More

Bio-Inspired Approach to RNA Delivery
Science Daily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
By delivering strands of genetic material known as messenger RNA (mRNA) into cells, researchers can induce the cells to produce any protein encoded by the mRNA. This technique holds great potential for administering vaccines or treating diseases such as cancer, but achieving efficient delivery of mRNA has proven challenging. More

KMC Systems Engineering & Manufacturing

KMC Systems is a leading provider of engineering services and contract manufacturing for the development, design and production of medical and life sciences instrumentation. We specialize in developing mechanized processes for tightly controlled and highly automated systems and manufacturing complex, highly-regulated instruments for the clinical environment.

High Gene-Therapy Costs Trigger Call for New Payment Models
Genetic Engineering & Biotechnology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The six-figure prices of new gene therapies will require payers, pharma companies, policymakers, and pharmacy benefit managers (PBMs) to develop new payment models that ensure patient access while reflecting the value delivered by the new treatments based on clinical outcomes, a top executive with PBM Express Scripts asserts. More

Inactivation of Porcine Endogenous Retrovirus in Pigs Using CRISPR-Cas9
Science Magazine    Share    Share on FacebookTwitterShare on LinkedinE-mail article
With the severe shortage of organs needed for transplants, xenotransplantation (transplantation of nonhuman organs to humans) offers an alternative source. Some pig organs have similar size and function to those of humans. The challenge is that the pig genome harbors porcine endogenous retroviruses (PERVs) that can potentially pass to humans with possibly damaging consequences. More


Research Scientist – Addiction Genomics
Binghamton University
US – NY – Binghamton

Formulation Chemist (Research and Development)
Kleen Test Products
US – WI – Port Washington

Software Product Manager
Labcyte, Inc.
US – CA – San Jose

Search Jobs at SLAS Career Connections



SLAS Point-to-Point
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Dennis Hall, Executive Editor, 469.420.2656   
Contribute news

This edition of SLAS Point-to-Point was sent to ##Email##. To unsubscribe from receiving SLAS Point-to-Point, click here. To unsubscribe from all SLAS e-mail communications, please click here. Did someone forward this edition to you? Subscribe here — it's free!

SLAS Terms of Use Policy

MultiView Privacy Policy 

Recent issues

Sept. 20, 2017
Sept. 13, 2017
Sept. 6, 2017
Aug. 30, 2017

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063